Immunotherapeutic approaches to paraneoplastic neurological disorders

Bibliography

• DALMAU J, GRAUS F: Paraneoplastic syndromes of thenervous system. In:Cancer of the nervous system. Loeffler JS (Ed.) Blackwell Scientific Publications, Oxford, UK. (1997):674–700.
   Google Scholar
• HEIDENREICH F, SCHOBER R, BRINCK U, HARTUNG HP:Multiple paraneoplastic syndromes in a patient with antibodies to neuronal nucleoproteins (anti-Hu).J. Neurol. (1995) 242(4):210–216.
   Google Scholar
• O'NEILL JH, MURRAY NMF, NEWSOM-DAVIS J: TheLambert-Eaton myasthenic syndrome. A review of 50 cases.Brain (1988) 11 1 (Pt 3):577–596.
   Google Scholar
• DALMAU J, GRAUS F, ROSENBLUM MK, POSNER JB:Anti-Hu associated paraneoplastic encephalomye-litis/sensory neuronopathy.Medicine (1 9 9 2) 71(2)59–72.
   Google Scholar
• •Detailed clinical description of 71 anti-Hu-positive patients.
   Google Scholar
• WILKINSON PC: Serologic findings in carcinomatous neuromyopathy.Lancet (1964) 1:1301–1303.
   PubMed Web of Science ®Google Scholar
• GRAUS F, VEGA F, DELATTRE JYet al. Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal antibodies.Neurology (1992) 42(3 Pt 1) 536–540
   Google Scholar
• DALMAU J, FURNEAUX HM, CORDON-CARDO C, POSNER-JB: The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues.Am. J. Pathol. (1992) 141 (4):881–886.
   Google Scholar
• VINCENT A, WILLCOX N: The role of T-cells in the initia-tion of autoantibody responses in thymoma patients.Pathol. Res. Pract. (1999) 195(8):535–540.
   Google Scholar
• ••An interesting paper on the role of T-cells in thymoma-associated myasthenia gravis.
   Google Scholar
• MOTOMURA M, LANG B, JOHNSTON I, PALACE J, VINCENT A, NEWSOM-DAVIS J: Incidence of serum anti-P/Q-type and anti-N-type calcium channel autoan-tibodies in the Lambert-Eaton myasthenic syndrome.Neurol. ScL (1997) 147(0:35–42.
   Google Scholar
• VINCENT A: Immunology of acetylcholine receptors in relation to myasthenia gravis.Physiol. Rev. (1980) 60(3)756–824.
   Google Scholar
• ROBERTS A, PERERA S, LANG B, VINCENT A, NEWSOM-DAVIS J: Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma cell line.Nature (1985) 317(6039):737–739.
   PubMed Web of Science ®Google Scholar
• LANG B, NEWSOM-DAVIS J, WRAY D, MURRAY N: Autoimmune etiology for myasthenic (Eaton-Lambert) syndrome.Lancet (1981) 2(8240):224.
   PubMed Web of Science ®Google Scholar
• ANDERSON NE, BUDDE-STEFFEN C, ROSENBLUM MKet Opsoclonus, myoclonus, ataxia and encephalopa-thyin adults with cancer: A distinct paraneoplastic syndrome.Medicine (1988) 67(2)100–109.
   Google Scholar
• LUQUE FA, FURNEAUX HM, FERZIGER Ret al.: Anti-Ri: An antibody associated with paraneoplastic opsoclonus and breast cancer.Ann. Neurol (1991) 29(3):241–251.
   Google Scholar
• YANG YY, YIN GL, DARNELL RB: The neuronal RNA-binding protein NOVA-2 is implicated as the autoantigen targeted in POMA patients with dementia.Proc. Natl. Acad. ScL USA (1998) 95(22):13254–13259.
   Google Scholar
• JAECKLE KA, GRAUS F, HOUGHTON A, CARDON-CARDO C, NIELSEN SL, POSNER JB: Autoimmune response of patients with paraneoplastic cerebellar degeneration to a Purkinje cell cytoplasmic protein antigen.Ann. Neurol (1985) 18(5):592–600.
   Google Scholar
• GRAUS F, DALMAU J, VALLDEORIOLA Fet al.: Immuno-logical characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease.J. Neuroimmunol. (1997) 74(1–2):55–61.
   Google Scholar
• DALMAU JO, POSNER JB: Neurological paraneoplastic syndromes.Neuroscientist (1998) 4(6)443–453.
   Google Scholar
• VERSCHUUREN JJ, DALMAU J, HOARD R, POSNER JB: Paraneoplastic anti-Hu serum: studies on human tumor cell lines.J. Neuroimmunol (1997) 79(2)202–210.
   Google Scholar
• GREENLEE JE, PARKS, TN, JAECKLE KA: Type Ha (anti-Hu) antineuronal antibodies produce destruc-tion of rat cerebellar granule neuronesin vitro. Neurology (1993) 43(102049–2054.
   Google Scholar
• ADAMUS G, MACHNICKI M, SEIGEL GM: Apoptotic retinal cell death induced by antirecoverin autoantibodies of cancer-associated retinopathy.Invest. Ophthalmol Vis. ScL (1997) 38(2):283–291.
   Google Scholar
• •First study showing auto-antibody-induced apoptosis in paraneoplastic neuroophthalmological syndromes.
   Google Scholar
• TANAKA M, TANAKA K, ONODERA O, TSUJI S: Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody.Clin. Neurol. Neurosurg. (1995) 97(1):95–100.
   Google Scholar
• ALBERT ML, DARNELL JC, BENDER A, FRANCISCO LM, BHARDWAJ N, DARNELL RB: Tumor-specific killer cells in paraneoplastic cerebellar degeneration.Nature Med. (1998) 4(10:1321–1324.
   PubMed Web of Science ®Google Scholar
• ••Demonstration of tumour-specific T-cells and an effectiveantitumour immunity in patients with paraneoplastic cerebellar degeneration.
   Google Scholar
• VOLTZ R, DALMAU J, POSNER JB, ROSENFELD MR: T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis.Neurology (1998) 51 (4):1146–1150.
   PubMed Web of Science ®Google Scholar
• BENYAHIA B, LIBLAU R, MERLE-BÉRAL H, TOURANI JM, DALMAU J, DELATTRE JY: Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies.Ann. Neurol. (1999) 45 (2):162–167.
   Google Scholar
• CHALK CH, MURRAY NMF, NEWSOM-DAVIS Jet al.: Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma.Neurology (1990) 40(101552–1556.
   Google Scholar
• SANDERS DB: Lambert-Eaton myasthenic syndrome: clinical diagnosis, immune-mediated mechanisms and update on therapies.Ann. Neurol. (1995) 37 (Supp11):S63–73.
   Google Scholar
• NEWSOM-DAVIS J, MURRAY N, WRAY Det al.: Lambert-Eaton myasthenis syndrome: electrophysiological evidence for a humoral factor.Muscle Nerve (1982) 5 (9S):S17–20.
   Google Scholar
• NEWSOM-DAVIS J, MURRAY NMF: Plasmaexchange and immunosuppressive drug treatment in Lambert-Eaton myasthenis syndrome.Neurology (1984) 34 (4):480–485.
   PubMed Web of Science ®Google Scholar
• BAIN PG, MOTOMURA M, NEWSOM-DAVIS Jet al.: Effect of intravenous immunoglobulin (iv. Ig) treatment on muscle weakness and calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome.Neurology (1996) 47(3)678–683.
   Google Scholar
• VENUTA F, RENDINA EA, DE GIACOMO Tet al: Thymec-tomy for myasthenia gravis: a 27-year experience.Eur. J. Cardiothorac. Surg. (1999) 15(5):621–624.
   Google Scholar
• TOYKA KV: Myasthenia gravis. In:Current therapy in neurologic diseases III. Johnson RT (Ed.) BC Decker, Philadelphia, USA (1990):385–391.
   Google Scholar
• GAJDOS PH, CHEVRET S, CLAIR B, TRANCHANT C, CHASTANG C: Clinical-trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis.Ann. Neurol. (1997) 41(6)789–796.
   Google Scholar
• GRISOLD W, DRLICEK M, LISZKA-SETINEK U,WONDRUSCH E: Anti-tumour therapy in paraneoplas-tic neurological disease.Clin. Neurol Neurosurg. (1995) 97 (1):106–111.
   Google Scholar
• PETERSON K, ROSENBLUM MK, KOTANIDES MS, POSNER JB: Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody positive patients.Neurology (1992) 42(10):1931–1937.
   Google Scholar
• •Detailed description of the largest series of anti-Yo positive patients.
   Google Scholar
• OH SJ, DROPCHO EJ, CLAUSSEN GC: Anti-Hu associatedparaneoplastic sensory neuronopathy responding to early aggressive immunotherapy: report of two cases and review of the literature.Muscle Nerve (1997) 20(12)1576–1582.
   Google Scholar
• STARK E, WURSTER U, PATZOLD U, SAILER M, HAAS J:Immunological and clinical response to immunosup-pressive treatment in paraneoplastic cerebellar degeneration.Arch. Neurol. (1995) 52(8):814–818.
   Google Scholar
• RUSSO C, COHN SL, PETRUZZI MJ, ALARCON PA: Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblas-toma: a report from the pediatric oncology group.Med. Pediatr. Oncol. (1997) 28(4):284–288.
   Google Scholar
• GRAUS F, ABOS J, ROQUER J, MAZZARA R, PEREIRA A:Effect of plasmapheresis on serum and CSF autoanti-body levels in CNS paraneoplastic syndromes.Neurology (1990) 40(101621-1623.
   Google Scholar
• BATCHELOR TT, PLATTEN M, HOCHBERG FH: Immuno-adsorption therapy for paraneoplastic syndromes.J. Neurooncol. (1998) 40(2):131–136.
   Google Scholar
• •This paper provides immunoadsorption as a new therapeutic option in PND patients.
   Google Scholar
• MOLL JWB, HENZEN-LOGMANS SC, VAN DER MECHE FGA, VECHT CHJ: Early diagnosis and intravenous immunoglobulin therapy in paraneoplastic cerebellar degeneration.J. Neurol. Neurosurg. Psychiatry (1993) 56(0: 112.
   Web of Science ®Google Scholar
• COUNSELL CE, MCLEOD M, GRANT R: Reversal of subacute paraneoplastic cerebellar syndrome with intravenous immunoglobulin.Neurology (1994) 44(6):1184–1185.
   PubMed Web of Science ®Google Scholar
• GUY J, APTSIARI N: Treatment with paraneoplasticvisual loss with intravenous immunoglobulin: report of three cases.Arch. Opthalmol (1999) 117(4):471–477.
   Google Scholar
• UCHUYA M, GARUS F, VEGA F, RENE F, DELATTRE JY:Intravenous immunoglobulin treatment in paraneo-plastic neurological syndromes with antineuronal antibodies.J. Neurol. Neurosurg. Psychiatry (1996) 60 (4):388–392.
   Google Scholar
• •The only large study on iv. Ig in PND patients.
   Google Scholar
• BLAES F, STRITTMATTER M, MERKELBACH Set al.: Intravenous immunoglobulins in the therapy of paraneoplastic neurological disorders.J. Neurol. (1999) 246(4)299–303.
   Google Scholar
• DIETRICH G, KAZATCHKINE MD: Normal immuno-globulin G (IgG) for therapeutic use (intravenous Ig) contains anti-idiotypic specificities against an immunodominant, disease-associated cross-reactive idiotype of human anti-thyroglobulin autoantibodies.Clin. Invest. (1990) 85(3):620–629.
   Google Scholar
• KAZATCHKINE MD, DIETRICH G, HUREZ Vet al.: V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin.Immunol. Rev. (1994) 139(0:79–107.
   Google Scholar
• DALAKAS MC, ILLA I, DAMBROSIA JMet al.: A controlled trial of high-dose intravenous immunoglobulin infusions as a treatment of dermatomyositis.N Engl. J. Med. (1993) 329(27):1993–2000.
   Google Scholar
• KURLANDER RJ: Reversible and irreversible loss of Fe receptor function of human monocytes as a consequence of interaction with immunoglobulin G.J. Clin. Invest. (1980) 66(4):773–781.
   Google Scholar
• RIGAL D, VERMOT-DESROCHES C, HEITZ Set al.: Effects of iv. Ig in peripheral blood B, NK and T cell subpopu-lations in women with recurrent spontanous abortions: specific effect on LFA-1 and CD56 molecules.Clin. ImmunoL Immunopathol. (1994) 71(3):309–314.
   Google Scholar
• BLASCZYK R, WESTHOFF V, GROSSE-WILDE H: Soluble CD4, CD8 and HLA molecules in commercial immuno-globulin preparations.Lancet (1993) 341(8848)789–790.
   Google Scholar
• FAZEKAS F, DEISENHAMMER F, STRASSER-FUCHS S, NAHLER G, MAMOLI B: Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis: further analyses of the Austrian Immunoglobulin in MS study.Mult. Scler. (1997) 3(2):137–141.
   Google Scholar